Should I Switch To The Wegovy Pill?

The first GLP-1 pill was approved in the UK on the 11th June 2026. [1] If you’re using an injectable GLP-1 treatment and wondering whether to switch to the tablet version, we’re here to help you work out if that’s the right next step for you.

Article Summary:

• The Wegovy Pill is a daily tablet version of injectable Wegovy. It led to an average weight loss of 16.6% in 64 weeks in a clinical trial.
• The tablet must be taken every morning on an empty stomach, with no more than half a small glass of water, followed by a 30-minute wait before eating or drinking anything else.
• Wegovy tablets may work best for people who find injections difficult or nerve-wracking, travel often or prefer a more discreet treatment option. But, it may not be the right switch if you’re currently doing well on Mounjaro, have type 2 diabetes or have an unpredictable morning routine.

Is the Wegovy Pill right for me?

Wegovy tablets may suit your lifestyle more than an injectable pen if:

• Injections are a barrier to continuing treatment.
• You travel often and find storing injectable pens in the fridge a practical problem.
• You feel confident you can take a tablet first thing every morning on an empty stomach, then wait 30 minutes before eating, drinking or taking other medication consistently, long term.

However, oral Wegovy is probably not the right option for you if:

• You’re currently taking Mounjaro, as switching to the Wegovy pill may slow down your rate of weight loss, or in some cases lead to weight regain.
• Your mornings are unpredictable (for example due to shift work, early starts or irregular schedules), as the fasting and timing requirements may be difficult to maintain consistently.
• Your main goal is maximising the percentage of body weight you lose.

How effective is the Wegovy Pill?

Oral Wegovy contains the same active ingredient as injectable Wegovy: semaglutide. But, it’s delivered as a daily tablet rather than a weekly injection.

In a clinical trial, people using oral Wegovy (semaglutide 25mg) lost 16.6% of their starting body weight on average in 64 weeks (1 year, 3 months). [2]

This result is comparable to injectable Wegovy (semaglutide 2.4mg), which showed an average weight loss of 16.9% in 68 weeks (1 year, 4 months). [3]

Why does the Wegovy Pill require a strict morning routine?

Wegovy tablets must be taken in a very specific way because of how it’s absorbed in the body. The tablet contains an ingredient called SNAC, which helps the medicine pass through the stomach lining.

To help this work properly, the tablet should be taken first thing in the morning on an empty stomach, before food, coffee or any other drink. The tablet should be swallowed with only a small amount of plain water, no more than 120ml which is roughly half a small glass. After this, you should wait at least 30 minutes before eating, drinking anything else or taking other oral medications.

If the instructions aren’t followed, your body may absorb less of the medicine. This can make it less effective, and may impact your weight loss results.

This routine needs to be followed every day, with no breaks. Some people might find this routine harder to stick to than a weekly injection, so it’s important to understand it before switching treatment so you can decide if it’s the right fit for you.

Should I stay on injectable treatments?

If you’re currently using Mounjaro and it’s working well for you, switching to Wegovy tablets may lead to less weight loss on average. [2, 4] But, this doesn’t mean you should stay on Mounjaro if the injections are difficult or not right for you.

If you’re currently using injectable Wegovy, oral Wegovy may lead to similar results for some people. [2, 3] It may be an option to consider if you are entering a phase of weight maintenance and would prefer to avoid injections long-term. This option would work best if you’re confident you can take a daily tablet consistently every morning, exactly as prescribed. Missing doses, or not following the fasting instructions, can reduce how well the Wegovy tablets work.

If you switch from injectable Wegovy (semaglutide 2.4mg) to oral Wegovy, the highest dose (25mg) is recommended to achieve a similar rate of weight loss. You may choose to start at a lower dose with support from our clinical team, but you would need to gradually increase your dose over time to get the full benefit. This step-up period may temporarily slow weight loss progress, and some people might notice weight regain during this time.

People with type 2 diabetes often lose slightly less weight with GLP-1 treatments compared with people without diabetes. With oral Wegovy, this difference may be greater because type 2 diabetes can affect how well the tablet is absorbed. As of June 2026, injectable GLP-1 medications are considered the more effective option for people with type 2 diabetes looking to achieve significant weight loss. [5]

Are the side effects of the Wegovy Pill better or worse than with injectable treatments?

As oral Wegovy belongs to the class of medications known as GLP-1 receptor agonists, side effects are similar to that of injectable Wegovy and Mounjaro. But, there are two important differences*:

1. Vomiting may be more common with oral Wegovy. In a clinical trial, around 3 in 10 people experienced vomiting with oral Wegovy (semaglutide 25mg), compared with 2 in 10 people with injectable Wegovy (semaglutide 2.4mg) and around 1 in 10 Mounjaro (tirzepatide 15mg). [2-4] This may be linked to the way the tablet is absorbed through the stomach lining.
2. Because oral Wegovy is a tablet, there’s no risk of injection site reactions such as redness, bruising or discomfort from injections. This can be a real benefit for people who dislike injections or experience problems with them.

*This information comes from separate clinical trials and should be interpreted with caution, as study designs and populations were not identical.

What are the advantages of the Wegovy Pill?

• There are no injections. For some people, fear or worry about needles can make it difficult to continue treatment. Taking a tablet instead of using an injection can make treatment feel much easier to manage.
• The tablets don’t need to be kept in the fridge. Unlike injectable pens, Wegovy tablets can be carried in its original packaging at room temperature. This can make travelling simpler.
• The Wegovy Pill is more private and discreet. A tablet looks like any other daily medication, with no needles, pens or sharps bins involved.

If you’re already using an injectable GLP-1 treatment and it’s working well for you, it’s likely you would be advised to continue with your current treatment. Switching to Wegovy tablets isn’t likely to improve weight loss results, and may even slow your progress or lead to weight regain.

But, if there are specific reasons you’d prefer an oral tablet (such as injection site reactions, frequent travel, or you’re finding injections difficult to manage), switching to the Wegovy Pill may be an option to consider.

Any switch should be made with a clear understanding of what to expect, and with confidence to follow the daily morning routine that comes with the Wegovy tablets consistently in the long term.

At MedExpress, we offer online consultations with regular clinical check-ins, and a range of weight loss treatments including Mounjaro, injectable Wegovy and the Wegovy Pill (coming soon, join our waitlist) and our team can help you find the right treatment for you.

References

1. Medicines and Healthcare products Regulatory Agency. First GLP-1 tablet for weight loss approved in the UK [Internet]. London: GOV.UK; 2026 Jun 11 [cited 2026 Jun 15]. Available from: GOV.UK
2. Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, Shaji C, Rubino D, Garvey WT; OASIS 4 Study Group. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025 Sep 18;393(11):1077-1087. doi: 10.1056/NEJMoa2500969. PMID: 40934115.
3. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
4. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
5. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.